Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.74 |
| ▸ | OSBP | P22059 | 4/20 | 0.73 |
| ▸ | RORC | P51449 | 4/20 | 0.73 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.73 |
| ▸ | OSBP2 | Q969R2 | 2/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.73 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.73 |
| ▸ | POLA1 | P09884 | 1/20 | 0.66 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.65 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.62 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.62 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.62 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.61 |
| ▸ | CRYAB | P02511 | 1/20 | 0.59 |
| ▸ | HMGCR | P04035 | 1/20 | 0.59 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.59 |
| ▸ | ITGAV | P06756 | 1/20 | 0.59 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.59 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.59 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28185721 | 1.00 | USP2 (0.74) | USP2OSBPRORCCYP46A1OSBP2 | |
| SCHEMBL932451 | 1.00 | USP2 (0.74) | USP2OSBPRORCCYP46A1OSBP2 | |
| SCHEMBL14052247 | 1.00 | USP2 (0.74) | USP2OSBPRORCCYP46A1OSBP2 | |
| SCHEMBL24264118 | 1.00 | USP2 (0.74) | USP2OSBPRORCCYP46A1OSBP2 | |
| SCHEMBL14558147 | 1.00 | USP2 (0.74) | USP2OSBPRORCCYP46A1OSBP2 | |
| SCHEMBL24927685 | 1.00 | USP2 (0.74) | USP2OSBPRORCCYP46A1OSBP2 | |
| SCHEMBL11977916 | 1.00 | USP2 (0.74) | USP2OSBPRORCCYP46A1OSBP2 | |
| SCHEMBL18409785 | 1.00 | USP2 (0.74) | USP2OSBPRORCCYP46A1OSBP2 | |
| SCHEMBL7601730 | 1.00 | USP2 (0.74) | USP2OSBPRORCCYP46A1OSBP2 | |
| SCHEMBL17715402 | 1.00 | USP2 (0.74) | USP2OSBPRORCCYP46A1OSBP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106967213-B | Eight-arm polyethylene glycol, preparation method, functionalized derivative and modified biologically-relevant substance | 厦门赛诺邦格生物科技股份有限公司 | 2019-11-05 | — | — | CN | claimed |
| CN-106967213-A | Eight-arm polyethylene glycol, preparation method, functionalized derivative and modified biologically-relevant substance | 厦门赛诺邦格生物科技股份有限公司 | 2017-07-21 | — | — | CN | claimed |
| US-20220119428-A1 | PHOSPHOLIPIDATION OF IMIDAZOQUINOLINES AND OXOADENINES | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-04-21 | — | — | US | disclosed |
| US-11248012-B2 | Phospholipidation of imidazoquinolines and oxoadenines | GLAXO SMIIHKLINE BIOLOGICALS SA (BE) | 2022-02-15 | — | — | US | disclosed |
| US-20210024553-A1 | PHOSPHOLIPIDATION OF IMIDAZOQUINOLINES AND OXOADENINES | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2021-01-28 | — | — | US | disclosed |
| EP-3238738-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | Arbutus Biopharma Corporation (CA) | 2017-11-01 | — | — | EP | disclosed |
| EP-2355658-B1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORP (CA) | 2017-09-27 | — | — | EP | disclosed |
| US-9764036-B2 | Lipids and compositions for the delivery of therapeutics | ARBUTUS BIOPHARMA CORPORATION (CA) | 2017-09-19 | — | — | US | disclosed |
| EP-3207944-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | Arbutus Biopharma Corporation (CA) | 2017-08-23 | — | — | EP | disclosed |
| US-9707292-B2 | Lipids and compositions for the delivery of therapeutics | ARBUTUS BIOPHARMA CORPORATION (CA) | 2017-07-18 | — | — | US | disclosed |
| US-9682139-B2 | Lipids and compositions for the delivery of therapeutics | ARBUTUS BIOPHARMA CORPORATION (CA) | 2017-06-20 | — | — | US | disclosed |
| US-20110311582-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2011-12-22 | — | — | US | disclosed |
| WO-2010054406-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010054405-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010054401-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010054384-A1 | LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
| US-4183847-A | STANDARD FOR DETERMING CHOLESTEROL CONTENT | MONOBIND, INC., A CORP. OF CA. | 1980-01-15 | — | — | US | disclosed |
| US-4175074-A | Serum-soluble cholesterol compounds and method for their preparation | MONOBIND, INC., A CORP. OF CA. | 1979-11-20 | — | — | US | disclosed |
| US-4042330-A | In a method for checking the accuracy of a test using an enzymatically hydrolyzable, serum-soluble cholesterol compound | MONOBIND, INC., A CORP. OF CA. | 1977-08-16 | — | — | US | disclosed |
| US-4040784-A | Method for checking the accuracy of a test, using a serum-soluble cholesterol compound | MONOBIND, INC., A CORP. OF CA. | 1977-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024553-A1 | PHOSPHOLIPIDATION OF IMIDAZOQUINOLINES AND OXOADENINES | TLR7, TLR8, TLR9 | USP2 2771/4885OSBP 358/4885RORC 1747/4885 |
| US-20220119428-A1 | PHOSPHOLIPIDATION OF IMIDAZOQUINOLINES AND OXOADENINES | TLR7, TLR8, TLR9 | USP2 2749/4885OSBP 347/4885RORC 1716/4885 |
| US-20110311582-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | APOB, LPAR3, LPAR2 | USP2 2744/4885OSBP 674/4885RORC 3461/4885 |
| US-11248012-B2 | Phospholipidation of imidazoquinolines and oxoadenines | TLR7, TLR8, TLR9 | USP2 2771/4885OSBP 358/4885RORC 1747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.